|
|
Article: Crohn's Drug Fails In Phase II; Millennium Awaits More Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Although its treatment for Crohn's disease missed the primary endpoint in a Phase II trial, Millennium Pharmaceuticals Inc. said the drug hit a secondary endpoint and the company is awaiting results from another Phase II study, this one for ulcerative colitis, with the monoclonal antibody MLN02.
"The diseases are similar, but there are important differences," said John Maraganore, senior vice president of strategic product development for Cambridge, Mass.-based Millennium. He said the trials are different, too, "in terms of patients at entry and how we measure the primary endpoint."
Millennium's shares (NASDAQ:MLNM) dipped 13 ...